Clinical Trial Update: Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety and immunogenicity study of a tetanus, diphtheria, and acellular pertussis (Tdap) vaccine developed by Green Cross Corporation; the status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• Tdap vaccine (Diphtheria, tetanus, and pertussis vaccine (Tdap))

Snippet

Sponsor: Green Cross Corporation | Conditions: Tetanus, Diphtheria | Phase 1, Phase 2 | Status: UNKNOWN